文献速递肺血管病与心包/心肌炎血脂与心血管预防

贝派地酸对的他汀不耐受外周动脉疾病患者肢体结局的影响:CLEAR Outcomes 试验分析

Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: Insights From the CLEAR Outcomes Trial.
PubMed 文献 · Circulation · 2026-08-18

该研究基于 CLEAR Outcomes 随机对照试验,纳入基线有外周动脉疾病(PAD)的他汀不耐受患者 1624 例,评估贝派地酸 180 mg 对主要不良肢体事件(MALE)的影响。中位随访 40.6 个月,贝派地酸使首次 MALE 风险降低 36%,总 MALE 降低 45%,支持在该人群中强化降脂以降低整体血管风险。

要点

  • 贝派地酸使 PAD 患者首次 MALE 风险降低 36%(HR 0.64,95%CI 0.44-0.93)。
  • 贝派地酸使 PAD 患者总 MALE 降低 45%(RR 0.55,95%CI 0.35-0.85)。
  • PAD 亚组内首次 MACE-4 或 MALE 的降低未达统计学显著。

核心结论

  • 在动脉粥样硬化性血管疾病患者中,贝派地酸同时降低 MACE 与 MALE,在 PAD 患者中绝对获益明显。
  • 结果支持在 PAD 患者中降低低密度脂蛋白胆固醇以降低整体血管风险,并支持贝派地酸在该人群中的应用。

研究设计与样本

  • 基线由研究者报告临床 PAD 病史者共 1624 例,平均年龄 63.9±9.9 岁,女性 915 例(56.3%)。
  • MALE 由两名设盲的血管医学专家独立裁定,包括 PAD 症状加重导致血运重建、慢性肢体威胁性缺血和急性肢体缺血。
  • 结局按首次事件时间和总(含复发)事件评估,后者采用负二项方法。

主要发现

  • 安慰剂组 PAD 患者中 69 例(8.3%)在中位 40.6 个月内发生 MALE,复发事件率为 4.0%/年。
  • 贝派地酸使 MALE 风险降低 36%(HR 0.64,95%CI 0.44-0.93;P=0.018)。
  • 贝派地酸使总 MALE 降低 45%(RR 0.55,95%CI 0.35-0.85;P=0.007)。
  • 首次 MACE-4 或 MALE 总体降低 13%(HR 0.87,95%CI 0.80-0.95),PAD 亚组 HR 0.82(95%CI 0.64-1.04)未达统计学显著。
  • 总 MACE-4 或 MALE 总体降低(RR 0.81,95%CI 0.73-0.90),PAD 亚组 RR 0.71(95%CI 0.54-0.95)。

关键数值与推荐

  • 试验主要终点为 MACE-4,即心血管原因死亡、非致死性心肌梗死、非致死性卒中或冠状动脉血运重建。
  • 贝派地酸剂量为 180 mg,对照为安慰剂。
  • PAD 定义为基线研究者报告的临床病史。

临床怎么用

  • 对合并 PAD 的他汀不耐受动脉粥样硬化性血管疾病患者,可考虑使用贝派地酸以降低 MALE 与 MACE 风险。
  • 应重视 PAD 患者降低低密度脂蛋白胆固醇在减少整体血管风险中的作用。

局限性

  • PAD 亚组为基线临床病史报告,样本量 1624 例,亚组分析把握度有限。
  • PAD 亚组内首次 MACE-4 或 MALE 的降低未达统计学显著,解释需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with peripheral artery disease (PAD) are at high risk of major adverse limb events (MALE) and major adverse cardiovascular events (MACE). Recently, bempedoic acid was shown to reduce MACE in primary and secondary prevention patients. Whether bempedoic acid reduces the risk of MALE in patients with PAD is unknown. METHODS: CLEAR Outcomes (Cholesterol Lowering via Bempedoic Acid [ETC1002], an ACL-Inhibiting Regimen) randomized 13 970 patients to bempedoic acid 180 mg or placebo from December 22, 2016, to August 14, 2019. The trial primary end point was MACE-4, defined as death resulting from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization. A clinical history of PAD was reported by investigators at baseline. Two blinded vascular medicine specialists independently adjudicated MALE, including adverse events indicating worsening PAD symptoms leading to revascularization, chronic limb-threatening ischemia, and acute limb ischemia. Outcomes were assessed as time to first event and total (including recurrent) events with a negative binomial approach. RESULTS: A total of 1624 of the enrolled patients (mean±SD age, 63.9±9.9 years; 915 [56.3%] female) had PAD at baseline. In patients with PAD in the placebo group, 69 (8.3%) had MALE over a median of 40.6 months, with rate of recurrent events of 4.0%/y. Bempedoic acid reduced the risk of MALE by 36% (hazard ratio, 0.64 [95% CI, 0.44-0.93]; P=0.018). Bempedoic acid reduced total MALE by 45% (relative risk, 0.55 [95% CI, 0.35-0.85]; P=0.007). First MACE-4 or MALE was reduced overall by 13% (hazard ratio, 0.87 [95% CI, 0.80-0.95]) with consistent effects with PAD (hazard ratio, 0.82 [95% CI, 0.64-1.04]) and without PAD (hazard ratio, 0.87 [95% CI, 0.79-0.86]; Pinteraction=NS) but not statistically significant within the PAD subgroup alone. Total MACE-4 or MALE was reduced (relative risk, 0.81 [95% CI, 0.73-0.90]) overall with consistent effects in PAD (relative risk, 0.71 [95% CI, 0.54-0.95]) and without PAD (relative risk, 0.82 [95% CI, 0.73-0.92]; Pinteraction=NS). CONCLUSIONS: Patients with PAD are at high risk of MALE and MACE. Bempedoic acid reduces both MACE and MALE in patients with atherosclerotic vascular disease, with notable absolute benefits in patients with PAD. These findings support (1) the importance of lowering low-density lipoprotein cholesterol in patients with PAD to reduce overall vascular risk and (2) the benefits of bempedoic acid in this population.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Bonaca MP, Canonico ME, Li N, et al. Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: Insights From the CLEAR Outcomes Trial. Circulation. 2026. PMID: 42610264. doi:10.1161/CIRCULATIONAHA.125.078469

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。